43 results about "Plasma serum" patented technology

A method is provided for assessing allelic losses on specific chromosomal regions in melanoma patents. The method relies on the evidence that free DNA may be released in the plasma/serum of cancer patients allowing the detection of DNA with LOH in the plasma/serum of cancer patients by analysis for microsatellite markers. The amount of and specific allelic loss allows a prognosis to be made regarding tumor diagnosis and progression, tumor metastasis, tumor recurrence, and mortality.

The invention discloses a coronavirus rapid detection kit based on S protein ligand and ACE2 receptor competitive chromatography. The coronavirus rapid detection kit comprises quantum dot labeled ACE2protein, quantum dot labeled rabbit IgG, recombinant coronavirus spinous process protein S1, goat anti-rabbit IgG polyclonal antibody, an immunochromatographic test strip and other materials. The detection sensitivity is improved through quantum dot fluorescence labeling and multistage coupling amplification signals, the detection specificity is improved and the antibody research and developmentcycle is avoided by utilizing the ligand and receptor binding principle, the kit capable of rapidly detecting coronavirus is provided, and the biosafety in the detection process is guaranteed by establishing a virus inactivation system. The kit disclosed by the invention is suitable for detecting various biological samples and environmental samples such as oral mucosa liquid, respiratory tracts, whole blood, plasma, serum, excrement and the like, and can be applied to rapid detection of coronaviruses taking ACE2 as a receptor, such as SARS-CoV-19, SARS-CoV, HCoV-NL63 and the like.

The invention provides a multifunctional dry plate checkout console, and a preparation method and application thereof, belonging to the field of medical instrument. The multifunctional dry plate checkout console comprises a solid reaction carrier film (1) used for adsorbing biochemical reagent, a carbon fibre bar frame (2), a supporting pad (5) with the upper layer attached by thin fibreglass paper (3), a hard bracket (7) added by whole blood filter paper (4), and an elastic pad (6). The product of the invention is a disposable medical detection consumable belonging to quick micro-detection, can quantitatively/qualitatively and quickly detect a plurality of biochemical indexes in human body blood samples (whole blood, blood plasma and serum), with the detection process completed within 5 minutes; the preparation method and the application thereof have important significance for critical quick quantitative detection and disease diagnosis.

The invention discloses an LncRNA composition for detecting prognosis of an early esophageal cancer and a kit comprising the LncRNA composition. By fluorescent quantitative PCR, a sample (which can be tissues/plasma serum and the like) of a patient with an esophageal cancer and difference change of the expression amount of a group of LncRNA in a corresponding para-carcinoma tissue/reference sample are identified, and the risk of esophageal cancerrelapse or transfer is accurately evaluated early. The kit can be used for accurately detecting early esophageal cancer transfer potential, then the transfer or relapse risk of a postoperative esophageal cancer patient can be accurately predicted and evaluated, the patient with high risk is intensively monitored and intervened effectively, relapse or transfer of the esophageal cancer is reduced, and prognosis of the patient is improved further. The poor prognosis related lncRNA composition is adopted, and the shortcomings that sensitivity and specificity are low due to the fact that a kit only uses single lncRNA as a tumor marker, and therefore, rate of fault diagnosis and rate of missed diagnosis on the esophageal cancer are greatly increased are overcome.

The invention discloses a cirrhosis microRNA molecular marker composition, with sequence No. ranging from 1 to 13, as well as application of the molecular marker composition in preparing a cirrhosis personalized medicine diagnostic reagent. Due to a significant difference between content of a microRNA molecular marker of a cirrhosis patient in plasma/serum and content in plasma/serum in health control, cirrhosis patient can be effectively distinguished from people of the health control; in a process of applying medicines to the cirrhosis patient, administration can be stopped by guiding and assistance, when cirrhosis outcome microRNA molecular marker is adjusted to a normal level. Furthermore, the invention discloses a diagnostic kit for guiding personalized administration of the cirrhosis. The liver cirrhosis outcome microRNA molecular marker disclosed by the invention, when being used for guiding personalized administration of cirrhosis patients, has characteristics of being simple to operate, safe and noninvasive, high in specificity, high in sensitivity and easy in massive screening.

The invention belongs to the fields of molecular biology and medicine, and provides a plasma miRNA (micro Ribonucleic Acid) profile and an assay kit for predicting the curative effect of interferon on treatment of chronic hepatitis B. The miRNA profile comprises one or more miRNAs in SEQ ID NO1-11. Meanwhile, the invention provides corresponding high-efficiency and low-cost kit, assay chip and assay method. According to the plasma miRNA profile and the assay kit, the miRNA level in plasma and serum is assayed; and the plasma miRNA profile and the assay kit are suitable for being applied to clinically judging the effectiveness of interferon treatment. Compared with other known curative effect related factors, the expression profile is an independent prediction factor. Higher prediction accuracy can be achieved by combining the prediction profile with the ALT (Alanine Aminotransferase) level of a patient before treatment. The development of a personalized treatment plan is facilitated by combining the expression profile with HBV (Hepatitis B Virus) medicine resistance mutation analysis; and finally, the treatment cost is reduced and the proportion of complete response is increased.

The invention provides a micro-fluidic chip. When total blood flow passes through a bifurcated branch channel port, blood cells are subjected to asymmetric shearing force on two sides, the blood cellsselect a main channel with the large flow speed and the small flow resistance to continue to advance, and part of blood plasma can enter a bifurcated branch channel. According to the micro-fluidic chip, the micro-fluidic chip constructed through a bifurcated multi-branch structure can achieve whole blood separation without exogenous power. When the micro-fluidic chip performs flow resistance adjustment through a flow resistance adjusting unit 130 located in the bifurcated branch channel, the collection efficiency of the blood plasma is adjusted. According to the micro-fluidic chip, capillarydriving force is provided through a capillary pump unit 140 located at a tail end, the functions of quantifying and collecting plasma/serum are achieved, and finally on-chip self-driven whole blood separation is achieved. The micro-fluidic chip provided by the invention shows huge application potential in the field of integrated and micro-miniaturized bedside instant detection.

The invention provides a hepatitis b /hepatic cirrhosis microRNA molecular marker combination, which comprises more than one micro RNA nucleic acid molecules selected from mir.146a-5p, miR-22-3P and miR-381.3P, and a purpose of the marker combination for preparing hepatitis b/hepatic cirrhosis infection diagnosis and/or prognosis assessment kit. Due to a significant difference between content of a microRNA molecular marker of a hepatitis b/hepatic cirrhosis patient in plasma/serum and content in plasma/serum in health control, the hepatitis b/hepatic cirrhosis patient can be effectively distinguished from people of the health control; a chronic hepatitis b/hepatic cirrhosis disease state can be comprehensively analyzed, which can be used for guiding the patient treatment and usage of medication. The invention also provides a diagnostic kit for guiding the hepatitis b/hepatic cirrhosis infection diagnosis and/or prognosis assessment. By using the hepatitis b/hepatic cirrhosis microRNA molecular marker and the diagnostic kit, infection diagnosis and/or prognosis assessment of the hepatitis b/hepatic cirrhosis patient can be guided, and the combination has the characteristics of simple operation, safety and no wound, high specificity, high sensitivity and easy massive screening.

The invention provides a preparation method of prp serum for repairing sport injury, and relates to the technical field of serum preparation. The preparation method of the prp serum for sports injury repair comprises the following steps: conveying anticoagulant blood formed by mixing whole blood and an anticoagulant, carrying out secondary nanofiltration and centrifugation on the anticoagulant blood to obtain plasma serums with different concentrations, mixing platelet-rich plasma serums prepared in advance with the plasma serums with different concentrations to obtain prp serums with different concentrations, and refrigerating to obtain the prp serum for sports injury repair. The prp serum can be mixed with sodium hyaluronate gel to be injected into the sport injury part, the environment of natural cartilage is fully simulated by means of the gel with high water content, and the prp serum is easy to degrade and non-toxic, so that the curative effect research of the prp serum for repairing the sport injury is facilitated, the optimal treatment concentration scheme is obtained, and the quick repair of the sport injury part is promoted.

The invention belongs to the fields of molecular biology and medical science, and provides a blood plasma miRNA spectrum used for predicting the chronic hepatitis b curative effect of an interferon. The miRNA spectrum comprises one or a plurality of miRNA in SEQ ID No.1-10. The invention also provides a corresponding high-efficiency and low-cost kit, a detection chip and a detection method. The method and the kit provided by the invention are used for detecting miRNA levels in blood plasma and blood serum. The method and the kit are suitable to be used clinically for determining the effectiveness of an interferon. Compared to other known related factors, the expression spectrum is an independent prediction factor. The combination of the expression spectrum and HBV drug-resistance mutation analysis assists in the practice of individualized treatment schemes, and finally in reducing treatment costs and improving complete response proportions.

The invention discloses application of FXYD3 as a gastric cancer diagnosis marker and a treatment target, and relates to the technical field of medical biological detection. According to the invention, a specific detection primer is constructed, which can be used for gastric cancer diagnostic reagent or kit, and can be used for detecting tissue specimens or blood samples such as blood plasma, blood serum and blood platelets. The invention also comprises application of the FXYD3 in preparation of a pharmaceutical composition for preventing or treating gastric cancer, and the drug can inhibit expression of the FXYD3. The FXYD3 has an important function in the occurrence and progress of gastric cancer, which can be used as a target for diagnosis and treatment, and has a good clinical application value.

The invention discloses a method for detecting a high-density lipoprotein subcomponent in a preeclampsia judgment process, which comprises the following steps: presetting a high-density lipoprotein HDL subcomponent analysis kit, obtaining a blood sample, and detecting the to-be-detected blood sample by using the high-density lipoprotein HDL subcomponent analysis kit; carrying out standing centrifugal treatment on the blood sample, separating out plasma/serum, and adding the plasma/serum sample into a sample buffer solution containing lipophilic fluorescent dye, wherein the dye can be specifically combined with lipoprotein; injecting a gel dye into a microfluidic electrophoresis chip, adding a to-be-detected blood sample, performing detecting on a microfluidic electrophoresis chip analyzer,sending the sample into a separation channel under the action of an external electric field and electroosmotic flow, and separating HDL in the to-be-detected sample into a plurality of sub-componentsunder the action of a molecular sieve and charges. According to the structure, the judgment accuracy of preeclampsia is improved.

The invention discloses application of lncRNA SLC7A11-AS1 as a stomach cancer drug-resistance diagnosis marker and relates to the technical field of medical biological detection. The invention provides application of the lncRNA SLC7A11-AS1 as the stomach cancer drug-resistance diagnosis marker. The invention also constructs a stomach cancer drug-resistance diagnosis marker or kit containing a pairof specific detection primers to detect tissue specimens or blood samples such as plasma, serum and blood platelets. The lncRNA SLC7A11-AS1 has good clinical application values and has better detection effects on stomach cancer drug-resistance diagnosis.

The present invention provides a method for optimizing levels of mifepristone in a patient suffering from a mental disorder amenable to treatment by mifepristone. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1300 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1300 ng/mL.

The invention relates to the technical field of biological medicines, in particular to a long non-coding RNA (long non-coding RNA, lncRNA) coding polypeptide biomarker for brain glioma diagnosis and application thereof The invention relates to a biomarker of brain glioma. The biomarker is selected from one or more of lncRNA coding polypeptides in the following table; the biomarker is used for early diagnosis and/or recurrence detection of brain glioma. Based on the phenomenon that part of lncRNA coding polypeptide specifically exists in plasma/serum extracellular vesicles obtained in vitro by a glioma patient, and the phenomenon that specificity does not exist in plasma/serum extracellular vesicles obtained in vitro by normal people and other tumor patients, so that the lncRNA coding polypeptide can be used as a tumor marker of the glioma, the occurrence of the brain glioma can be quickly, accurately and clearly determined by detecting the expression profile and the expression quantity of the lncRNA coding polypeptide in plasma/serum extracellular vesicles obtained in vitro by a target patient through mass spectrometry.

The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.